Objective: The aim of this study was to investigate whether tapering down of combined estrogen plus progestogen therapy (EPT) reduced the recurrence of hot flashes and resumption of therapy compared with abrupt discontinuation. A secondary aim was to evaluate whether health-related quality of life (HRQoL) was affected after discontinuation of EPT and to investigate the possible factors predicting resumption of EPT.
A s many as 50% to 70% of women in the Western world experience menopause-related symptoms such as hot flashes and sweating 1<4 during the menopausal transition. Sleep disturbances and vaginal discomfort are other common symptoms associated with the menopausal transition. 3, 4 These symptoms may affect health-related quality of life (HRQoL). 5, 6 Previous observational 7<9 and randomized controlled studies investigating secondary endpoints 10, 11 reported the benefits of long-term use of hormone therapy (HT). The results from the Women's Health Initiative 12 and Heart Estrogen/Progestin Replacement Study 13 dramatically changed treatment recommendations of HT in both the United States and Europe and led to updated guidelines from national and international menopause societies. According to the current guidelines, HT is the most effective and safe therapy for symptomatic women in early postmenopause with moderate to severe vasomotor symptoms but should be used in the lowest effective dose and for the shortest possible duration. It is necessary to stop HT to evaluate whether the symptoms persist or have been resolved. An individual risk profile should be considered for every woman before initiation and after a failed attempt to discontinue HT. 14, 15 There is a lack of evidenced-based recommendations on how best to discontinue HT. Different types of gradual discontinuations are suggested either by Bdose taper,[ that is, decreasing the everyday dose, or Bday taper,[ that is, decreasing the number of days per week that HT is used. 16 Neither retrospective studies 17<20 nor prospective randomized controlled studies 21, 22 have shown significant differences in the recurrence of vasomotor symptoms or resumption of HT between gradual and abrupt discontinuation of HT. In these studies, both women with and women without hot flashes as indications for therapy have been included and changes in HRQoL have usually not been studied. Because a history of vasomotor symptoms before HT was initiated and recurrence of symptoms after discontinuation seem to be important factors for resuming HT, 17, 23 it would be of interest to specifically study symptom recurrence and the impact of discontinuation of HT on HRQoL in women who initiated HT because of vasomotor symptoms.
The hypothesis of this study was that tapering down continuous-combined estrogen plus progestogen therapy (EPT) would reduce the recurrence of hot flashes and the resumption of HT compared with abrupt discontinuation.
The aim of this randomized, prospective, open, controlled multicenter study was to compare the effects of two different methods used to discontinue continuous EPT, that is, tapering down or abrupt discontinuation, on the recurrence of hot flashes, resumption of therapy, and HRQoL in women with vasomotor symptoms before initiating EPT. We also investigated the possible predictors for resumption of HT.
METHODS

Participants
Postmenopausal women were consecutively invited to participate in the study by advertisement in local press or at visits to their gynecologist. Enrollment took place at 12 gynecological outpatient university-based or private clinics in Sweden between March 2005 and December 2007. Women were eligible if they had used HT for between 3 and 11 years, had used continuous EPT or tibolone at least during the last year, had originally started HT because of vasomotor symptoms, and were suitable to try to discontinue EPT according to the gynecologist's and her own judgment. The exclusion criteria were having unstable thyroid or other metabolic disease, having the indication to stop EPT rapidly (eg, breast cancer), having recently started or changed medication for any psychiatric disorder, undergoing other treatments for vasomotor symptoms, having more than one hot flash per 24 hours according to the 2-week screening diary, having had unsuccessful discontinuation of EPT during the last year, or undergoing EPT because of premenopausal hypogonadism.
The trial was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. Approval from the regional ethics board at Linkoping University was received before the study started. Written informed consent was obtained from all study participants before inclusion. An independent monitoring was performed to assure quality control during the study.
Intervention
Eligible women were planned to be equally randomized to either tapering down (taper group) or abrupt (abrupt group) discontinuation of EPT. The taper group was instructed to take their usual EPT dose every other day during 4 weeks, that is, day taper, before total discontinuation, and the abrupt group discontinued EPT immediately after randomization. A follow-up telephone interview was performed 6 weeks after discontinuation of EPT and 4 and 12 months after randomization ( Fig. 1 ).
An independent statistician prepared a computer-generated separate randomization list for each center and the randomization was carried out with blocks of four women. The randomization process and block lengths were unknown to the investigators and nurses participating in the study.
If the inclusion and exclusion criteria were met after the 2-week screening period, the study nurse allocated the next available number from the randomization list for the specific center and instructed the woman on how to discontinue the EPT.
Outcomes
The primary study variables were the median number and the severity of hot flashes per 24 hours in selfregistered diaries during the sixth week after the discontinuation of EPT. The secondary variables were the proportion of women who had resumed HT at the follow-up and the total score of HRQoL measured with the Psychological General Well-Being Index (PGWB). Adverse events were documented using open-ended questions at each contact. 
Measurements of study variables Hot flashes
To assess vasomotor symptoms, we used a manual hot flash diary during the 2-week screening period, 4-week tapering period (taper group), and 6 weeks after discontinuation of EPT (both groups). The woman registered her number and severity of hot flashes daily after waking up and before bedtime. The severity was subjectively rated with a scale ranging from 0 (not bothersome at all) to 10 (extremely bothersome) and consisted of a summative rating of all hot flashes experienced. The baseline average number and severity of flashes per 24 hours were calculated from the 2-week screening period, and the 6-week figure was calculated as an average of the 7 days of the sixth week. In nine women (five in the taper and four in the abrupt group) who resumed HT during the 6-week follow-up, the median number of days before reuptake was 26 days (range, 7-38 d). We did not analyze the diary registrations after reuptake of HT, but instead, the mean value of frequency and severity from the last 7 days for the specific woman, before she resumed HT, was carried forward to constitute the sixth-week data. With this procedure, about 5% of diary recordings were replaced. In addition, 22 women did not complete every recording during the sixth week and a similar carry-forward procedure was used, making us complete another 1.4% of missing values in incomplete diaries.
Health-related quality of life
The PGWB form was used to assess HRQoL at baseline and 6 weeks after the discontinuation of EPT. This selfadministered instrument has been validated and used to assess general psychological well-being 24 and has been validated in Swedish. 25 The PGWB form contains 22 items referring to anxiety, depressed mood, well-being, self-control, general health, and vitality. Each item is graded between 0 and 5, with a total score between 0 and 110. The value 0 is the most negative option, and 5 is the most positive option. In total, 4 (2.5%) of 162 questionnaires were missing, one baseline registration and three from the 6-week follow-up, and were replaced by group means for the visit concerned.
At the follow-up telephone interviews, the women were asked to grade their general health as Bunchanged,
Resumption of EPT
According to the protocol, at every contact, that is, at 6 weeks after discontinuation of EPT, 4 and 12 months after randomization, and at every unplanned contact, the study nurse asked if the woman had resumed treatment for menopause-related symptoms.
Answers to open-ended questions regarding whether any adverse events had occurred since the last contact were registered at all follow-up contacts.
Statistical methods
The assumption was that tapering down of EPT would lead to a mean recurrence of two hot flashes per 24 hours and abrupt discontinuation of EPT would cause 20% more hot flashes per 24 hours, that is, 2.4 flashes per 24 hours, 6 weeks after discontinuation. Standard deviation was estimated to be one hot flash per 24 hours. To obtain a power of 80%, we would need 100 women per group to detect a significant difference between groups (P G 0.05, two-sided test). An alternative power calculation was based on the assumption that 33% of women in the taper group and 66% of women in the abrupt group had resumed HT after 4 months. To obtain a power of 80%, we would need 35 women per group to detect a significant difference between groups (P G 0.05, two-sided test).
Because of a slow recruitment rate, probably due to the substantial decline in HT use in Sweden, and the fact that many women had tried to discontinue HT by themselves, the study was prematurely discontinued in December 2007 and the intended sample size of 200 women was not reached.
Data were analyzed according to Bintention to treat,[ that is, including all women who fulfilled the inclusion criteria (except HT 911 y), had no exclusion criteria, had initiated their change in EPT use according to randomization at least 1 day, and had any available measurements after randomization. In addition, we made analyses Bper protocol[ for primary and secondary outcomes, including only women who had completely followed the protocol.
Baseline and demographic data were described by using median and 25th to 75th percentiles (interquartile range). To compare differences between groups, Mann-Whitney U test was used for continuous variables. Proportions were compared by the use of Pearson W 2 test or Fisher's exact test when appropriate. Analysis of variance with repeated measures was used to compare hot flashes per 24 hours between the two groups from baseline to 6 weeks follow-up. Logistic regression analyses were used to establish which factors predicted the risk of resuming HT, both by entering all variables at the same time and with stepwise procedure.
The P value was set at G0.05 (two-sided) to be considered significant. Data analyses were performed by SPSS for Windows 14.0.0 standard version.
RESULTS
Study population
Of the 109 women screened for eligibility, 87 women were randomized to either taper-down (n = 46) or abrupt (n = 41) discontinuation of EPT (Fig. 2) . Four women were withdrawn from analyses because of protocol violations; that is, they did not meet inclusion or exclusion criteria. One woman withdrew her consent and one was lost to follow-up. Thus, baseline data included the remaining 81 women. Fourteen of these women (9 in the taper group and 5 in the abrupt group) had used HT for more than 11 years (12-21 y) but were kept in the analyses. The distribution of these women between the two groups was equal (P = 0.47). All analyses of primary and secondary outcomes were performed with and without these 14 women, and it appeared that the results were not affected if they were included. In the analyses of resumption of EPT, 
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the PGWB scores of all 81 women were included, whereas in the analyses of hot flashes, another 6 women were omitted because they had not filled in the diaries after baseline.
The women were 50 to 72 years old (median, 59.0 y; 25th-75th percentiles, 55-61 y). No differences in baseline and clinical characteristics were found between the two groups except that more women in the abrupt group smoked ( Table 1 ). In total, more than one third of the women used estradiol (E 2 ) 1 mg + norethisterone acetate 0.5 mg, about 25% used E 2 + medroxyprogesterone acetate, and approximately 10% used tibolone or E 2 2 mg + norethisterone acetate 1 mg. There were no differences between the groups regarding type of EPT use, medical history, and health status at screening (data not shown).
Hot flashes
The two groups did not differ regarding frequency or severity of hot flashes per 24 hours at baseline or at the sixth week after discontinuation of EPT (Table 2) , neither with intention to treat nor with per protocol analysis. Analyses of the frequency of hot flashes at daytime or nighttime separately yielded no further information. Repeated-measures analysis of variance indicated that flashes per day, per night, and per 24 hours increased significantly in both groups, but the change over time did not differ between the groups (P = 0.85).
The hot flash frequency per 24 hours at the sixth week did not differ between the groups of women who had or had not resumed HT at 6 weeks or at 4 months. In contrast, women who had resumed HT after 1 year had significantly more hot flashes at the sixth week than did women who still abstained from HT. Women who had resumed HT at 4 or 12 months reported significantly more severe hot flashes at the sixth week than did women who had not resumed therapy (Table 3 ).
In women in the abrupt group, who had recurrence of hot flashes and who had no flashes at all during the screening period, flashes appeared already 8.3 days (mean) after the last intake of HT versus 7.6 days (mean) in the taper group. Only three women in total did not have any recurrence of hot flashes at all during the 6-week diary period, two women in the taper group and one in the abrupt group.
Resumption
No significant differences were found between the two groups regarding resumption of HT at 6 weeks (6/45, 13.3% in the taper group; and 5/36, 13.9% in the abrupt group; P = 0.94), 4 months (16/45, 35.6% in the taper group; and 12/36, 33.3% in the abrupt group; P = 0.83), or 12 months (24/44, 55.0% in the taper group; and 14/36, 39.0% in the abrupt group; P = 0.12) after discontinuation of EPT. Analyses of the data per protocol yielded similar results.
Health-related quality of life
Total PGWB score did not differ at baseline (P = 0.25) or at the sixth week (P = 0.5) after discontinuation of EPT between the two randomization groups ( Table 2) . On the other hand, women who had resumed EPT at the 6-week follow-up (P = 0.005) and at the 4-and 12-month follow-ups (P G 0.001) had a significantly more pronounced decrease in PGWB total score at the sixth week compared with women who had not resumed HT at that time, whereas PGWB score did not differ at baseline between these groups ( Table 3 ). All the subscores of PGWB referring to anxiety, depressed mood, well-being, self-control, general health, and vitality decreased significantly between baseline and 6 weeks in women who had resumed HT within 4 months.
More women who had resumed HT at 4 months after randomization, compared with women who had not resumed HT at 4 months, reported, at the sixth-week telephone followup, that their general health had deteriorated (54% vs 26%; P = 0.04).
A logistic regression analysis including number and severity of hot flashes at 6 weeks, number of years with EPT, education, smoking habits, and change in PGWB score between baseline and 6 weeks showed that these factors together had an R 2 value (Nagelkerke) of 0.56 in explaining reuptake of HT after 12 months. The most important single predictor seemed to be the severity of hot flashes at 6 weeks, with an R 2 value (Nagelkerke) of 0.37 (P G 0.001). Also, the reduction in PGWB score from baseline to 6 weeks was an important factor, and together with the severity, it had an R 2 value (Nagelkerke) of 0.46. The odds ratio for the factor Bseverity of hot flashes at 6 weeks[ was 1.42 (95% CI, 1.19-1.69) with the stepwise method, thus similar to the result with all variables included (Table 4 ). We interpreted the results as indicating that the other variables did not confound this single variable. In addition, smoking habits predicted resumption of HT, but with borderline significance.
Adverse events
The proportion of women experiencing adverse events during the study was slightly, albeit not statistically, higher in the taper group than in the abrupt group, 39 (54%) women compared with 29 (48%) women, respectively. The most common adverse event in the total group was vaginal dryness (15%), joint pain (12%), depressed mood (11%), infections (7.5%), and sleep disturbances (6%). One woman in the abrupt 
DISCUSSION
This study failed to show any significant difference between women who tapered down EPT over 4 weeks and women who stopped abruptly regarding recurrence of vasomotor symptoms or resumption of HT. Four months after randomization, more than a third of the women had resumed HT, and after 1 year, almost 50% had resumed treatment, independently of randomization group. However, because of the premature discontinuation of the study, the statistical power is low, leading to a risk of not finding a significant difference between the two ways to discontinue EPT although it may really exist.
On the other hand, the women who resumed HT estimated the severity of flashes to be more pronounced and reported a greater impairment in HRQoL than did the women who did not resume HT. Our design, which has not been previously reported in other studies on the issue, with baseline PGWB measurements and another measurement 6 weeks after stopping EPT enabled us to state that women who resumed HT had a high PGWB score during HT but deteriorated after stopping HT. Thus, our data suggest that deteriorated wellbeing and the severity of hot flashes contributed to the women's decision to resume HT, which was confirmed in the logistic regression analysis. Several studies 26<29 have stated that HT has a positive impact on HRQoL, most evident in women with vasomotor symptoms and sleep disturbances. Whether severe flashes negatively affect HRQoL or if a generally negative quality of life makes women report more severe hot flashes cannot be analyzed with the present design. In addition, smoking decreased the risk to resume HT, which may be a result of women's belief that possible risks with HT may be increased by smoking.
The high rate of recurrence of hot flashes in our study may be related to the fact that all women had hot flashes before they once started HT and were long-term HT users (median, 9 y). It could be argued that the number of hot flashes was rather low, but evidently, the flashes experienced were severe enough to make the women resume HT. Factors such as hot flashes as an indication for starting HT, troublesome withdrawal symptoms after discontinuation of HT, hysterectomy, and long-term HT use have been reported as predictors for difficulty to stop HT successfully. 17, 20, 23 Haimov-Kochman et al 23 reported a more than twofold risk and Grady et al 17 reported a sevenfold increased likelihood for resuming HT with the first two above-mentioned factors. Long-term users also have experienced the benefits of HT use and may therefore be more prone to take up HT. Haimov-Kochman et al 23 found that the maximal severity score was equal in women who resumed HT and those who successfully quit HT, whereas in the latter group, symptoms declined more rapidly. They concluded that return to HT is expected in women intolerant to prolonged climacteric symptoms. This is in line with our findings that the proportion of women who had resumed HT increased from 6 weeks to 4 and 12 months.
Neither retrospective observational studies 17, 18 nor small, randomized controlled trials 21, 22 performed after the Women's Health Initiative study show any difference between gradual and abrupt discontinuation of HT. Haskell et al 30 suggested that women who chose the tapering method differ from those who chose the Bcold turkey[ method by being younger, more likely to use HT because of menopausal symptoms, long-term users, and more prone to use of alternative treatments. They found, however, that tapering was associated with lesser recurrence of menopausal symptoms but increased resumption of HT.
It has been reported that vasomotor symptoms will usually improve between a few months to a few years after onset, 4, 31 whereas 10% to 15% of women still have symptoms many years after onset. 32, 33 Our population, consisting of women, on average, 58 to 59 years of age and with long-time EPT use, still reported troublesome hot flashes after discontinuation of EPT. Possibly, our sample consisted of a subgroup of women who had prolonged vasomotor symptoms. These results are in line with data from a large, cross-sectional study showing that more than half of the women, between 50 and 60 years of age, with a history of moderate to severe hot flashes before initiating HT reported such symptoms after discontinuation. 20 The women included in the present study thus resemble those who today are well suited for HT according to current guidelines. Ness et al 19 reported similar results indicating that 40% of women younger than 65 years experienced vasomotor symptoms after discontinuation of HT. In a cross-sectional population-based study performed in Linköping, Sweden, 87% of women aged 53 to 54 years who initiated HT because of vasomotor symptoms experienced such symptoms when they discontinued HT, although more than half experienced less distressing symptoms than before they had started HT. 34 Grady et al 17 reported, in a cross-sectional study, that 30% of the women who stopped HT experienced troublesome vasomotor symptoms that began about 1 week after discontinuation of HT, in line with our results with recurrence after 7 to 8 days.
Haimov-Kochman et al 23 suggested a time frame of up to 3 months after discontinuation of HT as the period when the risk of resuming HT was highest. Others found that 25% to 50% of the women who stopped HT returned to HT mainly because of vasomotor symptoms within 6 months. 17, 35 In line with this, we found that more than a third of the women had resumed HT after 4 months.
In this study, the primary study variable was a subjective estimation of the number and severity of hot flashes. This method has been used in several studies and is considered to be a valid and reliable method. 36, 37 However, studies comparing subjectively and objectively registered vasomotor symptoms suggested a falsely low subjective reporting of hot flashes, between 43% and 60%. 38, 39 Thus, with objectively measured vasomotor symptoms, the frequency of hot flashes probably would have been higher, but it is unlikely that this would have affected the results.
A number of women did not complete every recording during the 6 weeks, and missing data were added by means of the carry-forward method. Of course, this is a weakness, but the proportion of missing data was below the limit of 5%, which is even recommended to be ignored. 40 We therefore do not consider that the missing data in our study may jeopardize the results.
We decided to follow the number and severity of flashes during the first 6 weeks after complete discontinuation of EPT. It would have been advantageous to have followed hot flashes with diaries for the first 4 months and to have measured PGWB again after resumption of HT. For practical reasons, however, we decided to limit the diaries to the first 6 weeks and could therefore relate resuming HT only to data obtained during the first 6 weeks.
In this study, a 4-week dosing-interval taper technique was used. Although it is possible that a longer taper-down period would have been better, prior studies have not indicated that the length of the tapering down period affects the outcome. 22 We suggest that more gradual tapering and longer duration of tapering should be tested prospectively.
It could be argued that the risk of symptom recurrence would differ in women with a high body mass index, in smokers, in women who regularly exercise, or in women with certain EPT preparations. We did not measure body mass index and exercise. The randomization should minimize the risk that these factors were not evenly distributed between our groups. It seemed that smokers were more common in the group of women who were randomized to abrupt discontinuation, but if anything, this would increase their risk of having recurrence of hot flashes, which the study could not confirm. Use of different EPT preparations was similar between the randomization groups, and therefore, we do not consider that this potential confounding factor jeopardizes our results. However, a study on a population using one specific regimen out of those used in the present study might have yielded other results that have been concealed with our design.
CONCLUSIONS
Our results indicate that women who initiate HT because of current guidelines (hot flashes) may experience recurrence of vasomotor symptoms and impaired HRQoL after discontinuation of HT regardless of the discontinuation method used, abrupt or taper down. Because, in addition to severity of hot flashes, decreased well-being was the main predictor of the risk to resume HT, it seems important to also discuss quality of life in parallel with efforts to discontinue HT.
